About Zealand Pharma
Zealand Pharma A/S is a Danish public (ZEAL.CO) biotechnology company focused on bringing novel peptide drugs forward in a cost efficient way to meet the needs of patients, caregivers and society and maximize shareholder value…Read more
Annual General Meeting
The Annual General Meeting of 2012 was held on 25 April 2012. Michael J. Owen was elected as a new board member. After the meeting, the board constituted itself with Jørgen Lindegaard as new Chairman and Daan J. Ellens as new Vice Chairman.
Product Pipeline
Zealand Pharma has a mature clinical pipeline of innovative peptide drugs, of which most are developed under partnerships. The lead invention is lixisenatide (Lyxumia®) filed for registration in Europe for Type 2 diabetes. Learn more about Zealand Pharma’s Product Pipeline.